Zeitschrift für Rheumatologie

, Volume 64, Issue 8, pp 564–575

Kardiovaskuläres Monitoring von Patienten mit systemischem Lupus erythematodes

ÜBERSICHT
  • 60 Downloads

Zusammenfassung

Eine frühzeitig einsetzende und beschleunigt fortschreitende Atherosklerose beeinflusst signifikant die Morbidität und Mortalität von Patienten mit systemischem Lupus erythematodes (SLE). Kardiale SLE-Manifestationen sind häufig, eine pulmonale Hypertonie tritt vielfach im Verlauf der Erkrankung auf. Die Häufigkeit kardiovaskulärer Komplikationen könnte prinzipiell ein regelmäßiges Monitoring von SLE-Patienten zur frühzeitigen Diagnosestellung und Therapie rechtfertigen. Diagnostische Verfahren zum Nachweis einer Koronarinsuffizienz, die Bestimmung von Surrogatmarkern der Atherosklerose und die Echokardiographie zeigen bei SLE-Patienten häufig auffällige Befunde. Bisher gibt es jedoch keine ausreichende Evidenz für den Nutzen eines routinemäßig durchgeführten kardiovaskulären Monitorings. In Anlehnung an Empfehlungen zu anderen Erkrankungen mit kardiovaskulären Folgen schlagen wir deshalb bei asymptomatischen SLE-Patienten eine Risikofaktorevaluation und echokardiographische Kontrollen in jährlichen Abständen vor. Bei Vorliegen von mindestens 2 Risikofaktoren empfehlen wir ein Belastungs-EKG. Der Nutzen eines solchen kardiovaskulären Monitorings für SLE-Patienten ist prospektiv zu untersuchen.

Schlüsselwörter

Lupus, systemischer erythematodes  Herzerkrankung, koronare Kardiomyopathie Hypertonie, pulmonale Monitoring 

Cardiovascular monitoring of patients with systemic lupus erythematosus

Summary

Accelerated atherosclerotic cardiovascular disease is increasingly recognized as a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Cardiac manifestations of SLE are frequent and can involve almost all components of the heart. Pulmonary hypertension often develops during the course of SLE. The high incidence of cardiovascular complications may justify a screening of SLE patients in order to ensure early diagnosis and therapy. Results of diagnostic procedures that detect coronary insufficiency, surrogates of atherosclerotic burden and echocardiographic findings are often abnormal in SLE. However, evidence to support a routine screening for cardiovascular disease is currently not available. Therefore, based on the recommendations that have been proposed for other conditions associated with cardiovascular disease, we suggest assessment of risk factors and the performance of echocardiography at least annually in asymptomatic SLE patients. If two or more risk factors are present, an exercise ECG is recommended. The benefit, however, of screening SLE patients for cardiovascular disease has to be confirmed in prospective studies.

Key words

Systemic lupus erythematosus coronary heart disease cardiomyopathy pulmonary hypertension monitoring 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000 patients. Medicine (Baltimore) 82:299–308PubMedGoogle Scholar
  2. 2.
    Trends in deaths from systemic lupus erythematosus–United States, 1979–1998. (2002) MMWR Morb Mortal Wkly Rep 51:371–374Google Scholar
  3. 3.
    Jacobsen S, Petersen J, Ullman S, Junker P, Voss A, Rasmussen JM et al (1999) Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. Scand J Rheumatol 28:75–80PubMedGoogle Scholar
  4. 4.
    Abu-Shakra M, Urowitz MB, Gladman DD, Gough J (1995) Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 22:1259–1264PubMedGoogle Scholar
  5. 5.
    Ward MM, Pyun E, Studenski S (1995) Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort. Arthritis Rheum 38:1492–1499PubMedGoogle Scholar
  6. 6.
    Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA (1976) The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60:221–225CrossRefPubMedGoogle Scholar
  7. 7.
    Schattner A, Liang MH (2003) The cardiovascular burden of lupus: a complex challenge. Arch Intern Med 163:1507–1510CrossRefPubMedGoogle Scholar
  8. 8.
    Wajed J, Ahmad Y, Durrington PN, Bruce IN (2004) Prevention of cardiovascular disease in systemic lupus erythematosus–proposed guidelines for risk factor management. Rheumatology (Oxford) 43:7–12CrossRefPubMedGoogle Scholar
  9. 9.
    Bulkley BH, Roberts WC (1975) The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 58:243–264CrossRefPubMedGoogle Scholar
  10. 10.
    Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP et al (1999) Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 42:51–60CrossRefPubMedGoogle Scholar
  11. 11.
    Jonsson H, Nived O, Sturfelt G (1989) Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 68:141–150PubMedGoogle Scholar
  12. 12.
    Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jr., Jansen-McWilliams L et al (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145:408–415PubMedGoogle Scholar
  13. 13.
    Sturfelt G, Eskilsson J, Nived O, Truedsson L, Valind S (1992) Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients from a defined population. Medicine (Baltimore) 71:216–223PubMedGoogle Scholar
  14. 14.
    Haider YS, Roberts WC (1981) Coronary arterial disease in systemic lupus erythematosus; quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years. Am J Med 70:775–781CrossRefPubMedGoogle Scholar
  15. 15.
    Ward MM (1999) Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42:338–346PubMedGoogle Scholar
  16. 16.
    Petri M, Perez-Gutthann S, Spence D, Hochberg MC (1992) Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 93:513–519CrossRefPubMedGoogle Scholar
  17. 17.
    Petri M (2000) Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 9:170–175CrossRefPubMedGoogle Scholar
  18. 18.
    Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH (1996) Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 348:1120–1124CrossRefPubMedGoogle Scholar
  19. 19.
    Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du BR et al (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44:2331–2337CrossRefPubMedGoogle Scholar
  20. 20.
    Ross R (1999) Atherosclerosis–an inflammatory disease. N Engl J Med 340:115–126CrossRefPubMedGoogle Scholar
  21. 21.
    Tedesco F, Fischetti F, Pausa M, Dobrina A, Sim RB, Daha MR (1999) Complement-endothelial cell interactions: pathophysiological implications. Mol Immunol 36:261–268CrossRefPubMedGoogle Scholar
  22. 22.
    Schonbeck U, Varo N, Libby P, Buring J, Ridker PM (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104:2266–2268PubMedGoogle Scholar
  23. 23.
    Khamashta MA, Cervera R, Asherson RA, Font J, Gil A, Coltart DJ et al (1990) Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 335:1541–1544CrossRefPubMedGoogle Scholar
  24. 24.
    Vaarala O, Manttari M, Manninen V, Tenkanen L, Puurunen M, Aho K et al (1995) Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91:23–27PubMedGoogle Scholar
  25. 25.
    Vaarala O (1996) Antiphospholipid antibodies and atherosclerosis. Lupus 5:442–447PubMedGoogle Scholar
  26. 26.
    Tuhrim S, Rand JH, Wu XX, Weinberger J, Horowitz DR, Goldman ME et al (1999) Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 30:1561–1565PubMedGoogle Scholar
  27. 27.
    Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T (1997) Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 107:569–573CrossRefPubMedGoogle Scholar
  28. 28.
    Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U et al (2001) Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104:1887–1893PubMedGoogle Scholar
  29. 29.
    Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M (2002) Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 46:2957–2963CrossRefPubMedGoogle Scholar
  30. 30.
    Formiga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R (2001) Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 10:359–363CrossRefPubMedGoogle Scholar
  31. 31.
    Leong KH, Koh ET, Feng PH, Boey ML (1994) Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 21:1264–1267PubMedGoogle Scholar
  32. 32.
    Kahl LE (1992) The spectrum of pericardial tamponade in systemic lupus erythematosus. Report of ten patients. Arthritis Rheum 35:1343–1349PubMedGoogle Scholar
  33. 33.
    Mandell BF (1993) Pericardial effusion in patients with systemic lupus erythematosus: comment on the article by Kahl. Arthritis Rheum 36:1029–1030PubMedGoogle Scholar
  34. 34.
    Badui E, Garcia-Rubi D, Robles E, Jimenez J, Juan L, Deleze M et al (1985) Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients. Angiology 36:431–441PubMedGoogle Scholar
  35. 35.
    Doherty NE, Siegel RJ (1985) Cardiovascular manifestations of systemic lupus erythematosus. Am Heart J 110:1257–1265CrossRefPubMedGoogle Scholar
  36. 36.
    Chia BL, Mah EP, Feng PH (1981) Cardiovascular abnormalities in systemic lupus erythematosus. J Clin Ultrasound 9:237–243PubMedGoogle Scholar
  37. 37.
    Moder KG, Miller TD, Tazelaar HD (1999) Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 74:275–284PubMedCrossRefGoogle Scholar
  38. 38.
    Fairfax MJ, Osborn TG, Williams GA, Tsai CC, Moore TL (1988) Endomyocardial biopsy in patients with systemic lupus erythematosus. J Rheumatol 15:593–596PubMedGoogle Scholar
  39. 39.
    Roldan CA, Shively BK, Crawford MH (1996) An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 335:1424–1430CrossRefPubMedGoogle Scholar
  40. 40.
    Hojnik M, George J, Ziporen L, Shoenfeld Y (1996) Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93:1579–1587PubMedGoogle Scholar
  41. 41.
    Kao AH, Manzi S (2002) How to manage patients with cardiopulmonary disease? Best Pract Res Clin Rheumatol 16:211–227CrossRefPubMedGoogle Scholar
  42. 42.
    Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al (1987) Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107:216–223PubMedGoogle Scholar
  43. 43.
    Rich S (1998) Primary pulmonary hypertension. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998, Evian, France. http://www.who.int/ncd/cvd/pph.htmlGoogle Scholar
  44. 44.
    Simonson JS, Schiller NB, Petri M, Hellmann DB (1989) Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 16:918–925PubMedGoogle Scholar
  45. 45.
    Li EK, Tam LS (1999) Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol 26:1923–1929PubMedGoogle Scholar
  46. 46.
    Winslow TM, Ossipov MA, Fazio GP, Simonson JS, Redberg RF, Schiller NB (1995) Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J 129:510–515CrossRefPubMedGoogle Scholar
  47. 47.
    Asherson RA, Higenbottam TW, Dinh Xuan AT, Khamashta MA, Hughes GR (1990) Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 17:1292–1298PubMedGoogle Scholar
  48. 48.
    Okawa-Takatsuji M, Aotsuka S, Fujinami M, Uwatoko S, Kinoshita M, Sumiya M (1999) Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein. Clin Exp Immunol 116:174–180CrossRefPubMedGoogle Scholar
  49. 49.
    Quismorio FP, Jr., Sharma O, Koss M, Boylen T, Edmiston AW, Thornton PJ et al (1984) Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 13:349–359CrossRefPubMedGoogle Scholar
  50. 50.
    Inglesby TV, Singer JW, Gordon DS (1973) Abnormal fibrinolysis in familial pulmonary hypertension. Am J Med 55:5–14CrossRefPubMedGoogle Scholar
  51. 51.
    De Clerck LS, Michielsen PP, Ramael MR, Janssens E, Van Maercke YM, Van Marck EA et al (1991) Portal and pulmonary vessel thrombosis associated with systemic lupus erythematosus and anticardiolipin antibodies. J Rheumatol 18:1919–1921PubMedGoogle Scholar
  52. 52.
    Miyata M, Kida S, Kanno T, Suzuki K, Watanabe H, Kaise S et al (1992) Pulmonary hypertension in MCTD: report of two cases with anticardiolipin antibody. Clin Rheumatol 11:195–201CrossRefPubMedGoogle Scholar
  53. 53.
    Falcao CA, Alves IC, Chahade WH, Duarte AL, Lucena-Silva N (2002) Echocardiographic abnormalities and antiphospholipid antibodies in patients with systemic lupus erythematosus. Arq Bras Cardiol 79:285–291PubMedGoogle Scholar
  54. 54.
    Rubin LJ (1997) Primary pulmonary hypertension. N Engl J Med 336:111–117CrossRefPubMedGoogle Scholar
  55. 55.
    Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76–81PubMedCrossRefGoogle Scholar
  56. 56.
    Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334:296–302CrossRefPubMedGoogle Scholar
  57. 57.
    Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ et al (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322–329CrossRefPubMedGoogle Scholar
  58. 58.
    Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T (1997) Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 349:1365CrossRefPubMedGoogle Scholar
  59. 59.
    Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903CrossRefPubMedGoogle Scholar
  60. 60.
    Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D et al (2003) Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108:2066–2069CrossRefPubMedGoogle Scholar
  61. 61.
    Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N (2002) Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 29:282–287PubMedGoogle Scholar
  62. 62.
    Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR et al (1988) Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 78:1157–1166PubMedGoogle Scholar
  63. 63.
    Kullo IJ, Edwards WD, Schwartz RS (1998) Vulnerable plaque: pathobiology and clinical implications. Ann Intern Med 129:1050–1060PubMedGoogle Scholar
  64. 64.
    Sicari R, Pasanisi E, Venneri L, Landi P, Cortigiani L, Picano E (2003) Stress echo results predict mortality: a large-scale multicenter prospective international study. J Am Coll Cardiol 41:589–595CrossRefPubMedGoogle Scholar
  65. 65.
    Foltz WD, Al Kwifi O, Sussman MS, Stainsby JA, Wright GA (2003) Optimized spiral imaging for measurement of myocardial T2 relaxation. Magn Reson Med 49:1089–1097CrossRefPubMedGoogle Scholar
  66. 66.
    Matsunari I, Taki J, Nakajima K, Tonami N, Hisada K (2003) Myocardial viability assessment using nuclear imaging. Ann Nucl Med 17:169–179PubMedCrossRefGoogle Scholar
  67. 67.
    Sabharwal NK, Lahiri A (2003) Role of myocardial perfusion imaging for risk stratification in suspected or known coronary artery disease. Heart 89:1291–1297CrossRefPubMedGoogle Scholar
  68. 68.
    Budoff MJ, Diamond GA, Raggi P, Arad Y, Guerci AD, Callister TQ et al (2002) Continuous probabilistic prediction of angiographically significant coronary artery disease using electron beam tomography. Circulation 105:1791–1796CrossRefPubMedGoogle Scholar
  69. 69.
    Keelan PC, Bielak LF, Ashai K, Jamjoum LS, Denktas AE, Rumberger JA et al (2001) Long-term prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography. Circulation 104:412–417PubMedGoogle Scholar
  70. 70.
    Arad Y, Spadaro LA, Goodman K, Newstein D, Guerci AD (2000) Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol 36:1253–1260CrossRefPubMedGoogle Scholar
  71. 71.
    Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C (1991) Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 134:250–256PubMedGoogle Scholar
  72. 72.
    Grobbee DE, Bots ML (1994) Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 236:567–573PubMedCrossRefGoogle Scholar
  73. 73.
    O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK, Jr. (1999) Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340:14–22PubMedGoogle Scholar
  74. 74.
    Gottenberg JE, Roux S, Assayag P, Clerc D, Mariette X (2004) Specific cardiomyopathy in lupus patients: report of three cases. Joint Bone Spine 71:66–69CrossRefPubMedGoogle Scholar
  75. 75.
    Morguet AJ, Sandrock D, Stille-Siegener M, Figulla HR (1995) Indium-111-antimyosin Fab imaging to demonstrate myocardial involvement in systemic lupus erythematosus. J Nucl Med 36:1432–1435PubMedGoogle Scholar
  76. 76.
    Jolles PR, Tatum JL (1996) SLE myocarditis. Detection by Ga-67 citrate scintigraphy. Clin Nucl Med 21:284–286CrossRefPubMedGoogle Scholar
  77. 77.
    Paradiso M, Gabrielli F, Masala C, Coppotelli L, Di Franco M, Paoletti V et al (2001) Evaluation of myocardial involvement in systemic lupus erythematosus by signal-averaged electrocardiography and echocardiography. Acta Cardiol 56:381–386PubMedGoogle Scholar
  78. 78.
    Been M, Thomson BJ, Smith MA, Ridgway JP, Douglas RH, Been M et al (1988) Myocardial involvement in systemic lupus erythematosus detected by magnetic resonance imaging. Eur Heart J 9:1250–1256PubMedGoogle Scholar
  79. 79.
    Marangoni S, Quadri A, Dotti A, Scalvini S, Volterrani M, Schena M et al (1988) Noninvasive assessment of pulmonary hypertension: a simultaneous echo-Doppler hemodynamic study. Cardiology 75:401–408PubMedGoogle Scholar
  80. 80.
    Sella EM, Sato EI, Barbieri A (2003) Coronary artery angiography in systemic lupus erythematosus patients with abnormal myocardial perfusion scintigraphy. Arthritis Rheum 48:3168–3175CrossRefPubMedGoogle Scholar
  81. 81.
    Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF et al (2002) ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 106:1883–1892CrossRefPubMedGoogle Scholar
  82. 82.
    ACC/AHA Task Force on Practice Guidelines (2002) Step six: assign classification of recommendations and and strength of evidence. In: American College of Cardiology: Manual for ACC/AHA Guideline Writing Committees. Methodologies and Policies from the ACC/AHA Task Force on Practice Guidelines. http://www.acc.org/clinical/manual/manual_index.htmGoogle Scholar
  83. 83.
    Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS (1995) Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. Circulation 92:2157–2162PubMedGoogle Scholar
  84. 84.
    O’Rourke RA, Brundage BH, Froelicher VF, Greenland P, Grundy SM, Hachamovitch R et al (2000) American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation 102:126–140PubMedGoogle Scholar
  85. 85.
    Smith SC, Jr., Greenland P, Grundy SM (2000) AHA Conference Proceedings. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: executive summary. American Heart Association. Circulation 101:111–116PubMedGoogle Scholar
  86. 86.
    Screening for coronary heart disease: recommendation statement. (2004) Ann Intern Med 140:569–572Google Scholar
  87. 87.
    Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL et al (2003) ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr 16:1091–1110CrossRefPubMedGoogle Scholar
  88. 88.
    American Diabetes Association (2002) Standards of medical care for patients with diabetes mellitus. Diabetes Care 25:213–229Google Scholar
  89. 89.
    Hachulla E, Gressin V, Guillevin L, de Groote P, Cabane J, Carpentier P et al (2004) Pulmonary arterial hypertension in systemic sclerosis: definition of a screening algorithm for early detection (the ItinerAIR-Sclerodermie Study). Rev Med Interne 25:340–347PubMedGoogle Scholar
  90. 90.
    Codish S, Liel-Cohen N, Rovner M, Sukenik S, Abu-Shakra M (2004) Dobutamine stress echocardiography in women with systemic lupus erythematosus: increased occurrence of left ventricular outflow gradient. Lupus 13:101–104CrossRefPubMedGoogle Scholar
  91. 91.
    Hosenpud JD, Montanaro A, Hart MV, Haines JE, Specht HD, Bennett RM et al (1984) Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am J Med 77:286–292CrossRefPubMedGoogle Scholar
  92. 92.
    Lagana B, Schillaci O, Tubani L, Gentile R, Danieli R, Coviello R et al (1999) Lupus carditis: evaluation with technetium-99m MIBI myocardial SPECT and heart rate variability. Angiology 50:143–148PubMedCrossRefGoogle Scholar
  93. 93.
    Bruce IN, Burns RJ, Gladman DD, Urowitz MB (2000) Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities. J Rheumatol 27:2372–2377PubMedGoogle Scholar
  94. 94.
    Sun SS, Shiau YC, Tsai SC, Lin CC, Kao A, Lee CC (2001) The role of technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography (SPECT) in the detection of cardiovascular involvement in systemic lupus erythematosus patients with non-specific chest complaints. Rheumatology (Oxford) 40:1106–1111PubMedGoogle Scholar
  95. 95.
    Sella EM, Sato EI, Leite WA, Oliveira Filho JA, Barbieri A (2003) Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus. Ann Rheum Dis 62:1066–1070CrossRefPubMedGoogle Scholar
  96. 96.
    Manger K, Kusus M, Forster C, Ropers D, Daniel WG, Kalden JR et al (2003) Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 62:846–850CrossRefPubMedGoogle Scholar
  97. 97.
    Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S et al (2003) Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2407–2415CrossRefPubMedGoogle Scholar
  98. 98.
    Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R et al (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2399–2406CrossRefPubMedGoogle Scholar
  99. 99.
    Wolak T, Todosoui E, Szendro G, Bolotin A, Jonathan BS, Flusser D et al (2004) Duplex study of the carotid and femoral arteries of patients with systemic lupus erythematosus: a controlled study. J Rheumatol 31:909–914PubMedGoogle Scholar
  100. 100.
    Leung WH, Wong KL, Lau CP, Wong CK, Cheng CH (1990) Cardiac abnormalities in systemic lupus erythematosus: a prospective M-mode, cross-sectional and Doppler echocardiographic study. Int J Cardiol 27:367–375CrossRefPubMedGoogle Scholar
  101. 101.
    Crozier IG, Li E, Milne MJ, Nicholls MG (1990) Cardiac involvement in systemic lupus erythematosus detected by echocardiography. Am J Cardiol 65:1145–1148CrossRefPubMedGoogle Scholar
  102. 102.
    Leung WH, Wong KL, Lau CP, Wong CK, Cheng CH, Tai YT (1990) Doppler echocardiographic evaluation of left ventricular diastolic function in patients with systemic lupus erythematosus. Am Heart J 120:82–87CrossRefPubMedGoogle Scholar
  103. 103.
    Winslow TM, Ossipov MA, Fazio GP, Foster E, Simonson JS, Schiller NB (1993) The left ventricle in systemic lupus erythematosus: initial observations and a five-year follow-up in a university medical center population. Am Heart J 125:1117–1122CrossRefPubMedGoogle Scholar
  104. 104.
    Galve E, Candell-Riera J, Pigrau C, Permanyer-Miralda G, Garcia-Del-Castillo H, Soler-Soler J (1988) Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med 319:817–823PubMedCrossRefGoogle Scholar
  105. 105.
    Gleason CB, Stoddard MF, Wagner SG, Longaker RA, Pierangeli S, Harris EN (1993) A comparison of cardiac valvular involvement in the primary antiphospholipid syndrome versus anticardiolipin-negative systemic lupus erythematosus. Am Heart J 125:1123–1129CrossRefPubMedGoogle Scholar
  106. 106.
    Shen JY, Chen SL, Wu YX, Tao RQ, Gu YY, Bao CD et al (1999) Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int 18:147–151CrossRefPubMedGoogle Scholar
  107. 107.
    Pan TL, Thumboo J, Boey ML (2000) Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 9:338–342PubMedGoogle Scholar
  108. 108.
    Houman MH, Smiti-Khanfir M, Ben G, I, Miled M (2004) Systemic lupus erythematosus in Tunisia: demographic and clinical analysis of 100 patients. Lupus 13:204–211PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff-Verlag 2005

Authors and Affiliations

  • H. Schotte
    • 1
  • H. Becker
    • 1
  • W. Domschke
    • 1
  • M. Gaubitz
    • 1
  1. 1.Medizinische Klinik und Poliklinik BUniversitätsklinikum MünsterMünsterGermany

Personalised recommendations